Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher ...

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet ...